Israel Active

Recent studies show that the metabolite succinate, secreted by gut bacteria, can cause Inflammatory Bowel Disease (IBD). Scientists at Israel’s Ben Gurion University and in South Korea have developed therapeutic peptides to remove succinates from the body. Patents have been filed.

Researchers at Tel Aviv University have discovered that a type of white blood cell (eosinophils) can be utilized to fight cancer. They have a double effect, producing destructive proteins, while at the same time summoning the immune system’s cancer-fighting T-cells.

More details on the breakthrough technology of Israel’s Nectin (see previously). Monoclonal antibodies, with toxins attached, are sent directly to the cancer cell to break its ability to immobilize the body’s immune system. Clinical trials are expected to start in early 2022.

Researchers at Israel’s Weizmann Institute have developed a small molecule that stops the coronavirus spike protein from attaching to the lungs’ ACE2 receptor. But it doesn’t damage ACE2’s normal function. (See also for similarities with opaganib from Israel’s Redhill).

The Brilife vaccine, developed by the Israel Institute for Biological Research, appears to give long-term defense against the coronavirus. The 230 trial volunteers who received the highest dosage of the vaccine were still fully protected six months after vaccination.

A pre-clinical trial of opaganib from Israel’s Redhill (see previously) shows that its strong antiviral and anti-inflammatory activities can inhibit any variant of the SARS-Cov-2 virus. Opaganib targets SK2 - a key enzyme used by the virus to replicate, irrespective of spike protein mutations.

Israel’s Antidote Health is bringing a virtual Kupat Holim (health fund) to the US for the benefit of uninsured and under-insured Americans. Using a digital service and AI, Antidote Health says it can cut the costs of the service to about a tenth of what Americans pay now.

United Hatzalah EMT Gal was just in time when he used his own son’s EpiPen to save the life of a 5-year-old boy who suffered an anaphylactic reaction in Netanya. It was the birthday of the boy’s mother and she said that the life of her son was the best birthday present she had ever received.

In 2018, 24-year-old Netanel was shot in the head by a terrorist. Minimally conscious for several months, he is now making slow but steady recovery progress, against all odds, at Sheba Medical Center’s Brain Injury Rehabilitation Unit.

Israel’s illumigyn (see previously) has signed a Memorandum of Understanding with Dubai-based company DHI 2048 to deploy 2,500 units of its Gynescope cloud platform service. It will boost the availability of imaging and examination to improve women’s healthcare in the region.